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Respiratory tract infection with pneumoviruses (PVs) and paramyxoviruses (PMVs) 
are increasingly associated with chronic lung allograft dysfunction (CLAD) in lung 
transplant recipients (LTRs). Ribavirin may be a treatment option but its effectiveness 
is unclear, especially with respect to infection severity. We retrospectively analyzed 
10 years of PV/PMV infections in LTRs. The main end points were forced expira-
tory volume in 1 second (FEV1) at 3 and 6 months postinfection, expressed as a per-
centage of pre-infection FEV1 and incidence of new or progressed CLAD 6 months 
postinfection. A total of 139 infections were included: 88 severe infections (63%) 
(defined as >10% FEV1 loss at infection) and 51 mild infections (37%) (≤10% FEV1 
loss). Overall postinfection CLAD incidence was 20%. Associations were estimated 
on postinfection FEV1 for ribavirin vs no ribavirin (+13.2% [95% CI: 7.79; 18.67]) and 
severe vs mild infection (−11.1% [95% CI: −14.76; −7.37]). Factors associated with 
CLAD incidence at 6 months were ribavirin treatment (odds ratio (OR [95% CI]) 0.24 
[0.10; 0.59]), severe infection (OR [95% CI] 4.63 [1.66; 12.88]), and mycophenolate 
mofetil use (OR [95% CI] 0.38 [0.14; 0.97]). These data provide valuable information 
about the outcomes of lung transplant recipients with these infections and suggests 
possible associations of ribavirin use and infection severity with long-term outcomes. 
Well-designed prospective trials are needed to confirm these findings.
K E Y W O R D S
antibiotic: antiviral, clinical research/practice, infection and infectious agents – viral, 
infectious disease, lung (allograft) function/dysfunction, lung transplantation/pulmonology
2  |     ZWART eT Al.
1  | INTRODUC TION
Respiratory syncytial virus (RSV) and human metapneumovirus 
(hMPV), members of the family Pneumoviridae (PV), and parainfluenza 
virus (PIV) types 1-4, members of the family Paramyxoviridae (PMV) are 
recognized increasingly as causes of serious morbidity and mortality.1 
This morbidity is especially pronounced in lung transplant recipients 
(LTRs), where an acute mortality due to these infections has been re-
ported in up to 6%-20% of cases for individual viruses.2-5 In addition, 
PV/PMV infections are associated increasingly with the development 
of chronic lung allograft dysfunction (CLAD).3,6-10 CLAD is the primary 
factor limiting long-term survival after lung transplantation. It has a 
poor prognosis and is difficult to treat, which makes prevention par-
amount.11,12 Unfortunately, CLAD incidence ranging from 25%-67% 
have been described after untreated PV/PMV infections in LTR.5,6,8,9,13
Although, these virus infections do not seem to increase the risk 
of acute rejection,14,15 the severity of infection may be related to 
allograft dysfunction.7,16
Thus far the treatment options for these infections are limited, with 
some transplant centers currently using augmented steroids in combi-
nation with ribavirin.17 Ribavirin is a nucleoside analogue antiviral that 
is currently only registered as inhalation therapy for severe RSV infec-
tion and is used off label (increasingly in oral form) based on its in vitro 
activity against hMPV and PIV 1-4.18-20 Thus far, a limited number of 
small cohort studies have reported successful outcomes with ribavirin 
treatment for PV/PMV infections in LTR.2,21-24 However, the effective-
ness remains a matter of debate, as data from randomized studies are 
lacking. In this retrospective cohort study we aim to evaluate the course 
of lung function and incidence of new-onset or progression of CLAD in 
LTR with a PV/PMV infection, with or without ribavirin treatment.
2  | MATERIAL S AND METHODS
2.1 | Patients
This is a retrospective cohort study. All adult patients with a single-, 
double-, or heart-lung transplantation who were at least 6 months 
posttransplant and were diagnosed with an RSV, hMPV, or PIV1-4 
infection between 2008 and 2018 at the University Medical Centre 
Groningen were eligible for inclusion. If a patient had had multiple PV/
PMV infections over the years, only the first 2 cases were included 
(which had to be at least 1 year apart, else only the first case was in-
cluded). As part of regular care, chest x-ray and bacterial and fungal 
sputum cultures were performed in all patients to exclude other causes 
of lung function decline. Patients with factors that could interfere with 
reliable spirometry (eg, airway stenosis, chest wall pathology, pain), or 
who had a concomitant fungal infection, or had an episode of acute 
rejection within 3 months prior to PV/PMV infection were excluded.
The primary end point was the change in forced expiratory volume 
in 1 second (FEV1) at 6months postinfection, as a percentage of prein-
fection FEV1. Secondary end points were FEV1 at 3 months postinfec-
tion (as a percentage of preinfection FEV1), new-onset or progression 
of CLAD at 6 months postinfection, and change in hemoglobin level 
as a side-effect of ribavirin therapy. All patients had provided written 
informed consent for transplant-related research and the study was 
approved by the local ethics committee (METc 2015.452). The manu-
script was prepared in accordance with the Strenghtening Reporting of 
Observational studies in Epidemiology statement.25
2.2 | Pulmonary function
Spirometry was performed according to American Thoracic Society/ 
European Respiratory Society guidelines.26 FEV1 values at 4 time 
points were evaluated: preinfection, at infection, 3 months postin-
fection, and 6 months postinfection. Postinfection FEV1 values were 
expressed as a percentage of the preinfection baseline value to de-
termine recovery. Preinfection FEV1 is defined as the average of all 
the FEV1 values 4 months up to 2 weeks before infection. FEV1 at 
infection is defined as the lowest FEV1 during infection. Mild infec-
tions were defined as a ≤10% loss in this FEV1 at infection compared 
to the average of 4 months preinfection, whereas a >10% loss in 
FEV1 at infection compared to average of the 4 months preinfection 
was classified as severe infection.5,8
CLAD staging was characterized by a persistent (>3 months) FEV1 
decline of ≤80% of posttransplant baseline, with or without a change 
in forced vital capacity, according to the most recent International 
Society of Heart and Lung Transplantation criteria.27 New-onset 
CLAD was classified as a new diagnosis of CLAD in a CLAD-naïve 
patient (eg, CLAD stage 0 to CLAD stage 1 or higher); progressed 
CLAD was defined as progression to a higher CLAD stage in a patient 
with preexisting CLAD.
2.3 | Virologic diagnostics
PV/PMV infection was defined as a positive polymerase chain reac-
tion (PCR) test of a respiratory sample for RSV, hMPV, or PIV 1-4. 
Viral RNA detection was performed in nasopharyngeal swabs, nasal 
washes, sputum, or bronchoalveolar lavage specimens. RNA was 
extracted using the NucliSense EasyMag (bioMérieux). From 2008 
until 2014, all respiratory samples were tested by a laboratory-de-
veloped real-time PCR-test (LDT), using 1xTaqMan Fast Virus 1-Step 
Master Mix (Applied Biosystems), as described previously.28 From 
then onward the FilmArray respiratory panel (BioFire Diagnostics) 
was implemented in the laboratory alongside the LDT and used for 
priority testing of respiratory viruses, including RSV, hMPV, and PIV 
1-4. Results were available within 24 hours after sample collection 
for the LDT and within 3 hours for the FilmArray panel.
2.4 | Management of PV/PMV infections
Treatment in case of PV/PMV infection consisted of oral predni-
solone in combination with ribavirin or oral prednisolone only, and 
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was up to the discretion of the attending physician. Prednisolone 
was increased to 0.5 mg/kg/day in all patients for 7-10 days.5,21,29 
Suspected bacterial co-infection (indicated by purulent sputum 
production and/or infiltrate on chest x-ray without positive sputum 
culture) was treated up to the discretion of the attending physician. 
The immunosuppressive regimen was not changed based on the PV/
PMV infection. Until 2012 aerosolized ribavirin was used, which was 
thereafter replaced by an oral ribavirin regimen (200 mg, b.i.d., if 
<70 kg, 400 mg, b.i.d., if >70 kg, both 10-14 days). In 2015, a full oral 
treatment protocol adapted from Burrows et al22 was introduced, 
consisting of a high loading dose of ribavirin of 11 mg/kg t.i.d., in the 
first 24 hours, followed by a maintenance dose of 10 mg/kg, b.i.d., 
for 10-14 days. Maintenance dosing was halved in patients with 
an estimated GFR (eGFR) <50 mL/min. Anemia was classified as a 
hemoglobin level <13.0 g/dL for men or <12.0 g/dL for women.30
2.5 | Statistical analysis
Medians were compared using the nonparametric Mann-Whitney U test 
or the Kruskal-Wallis H test, proportions using the Fisher exact test or 
the chi-square test. FEV1 3- and 6-months postinfection was simulta-
neously analyzed using a hierarchical linear mixed-effects model. Time 
since transplantation, PV/PMV species (RSV, hMPV, or PIV), viral co-
infection or not, bacterial co-infection or not, presence of CLAD pre-
infection, severe or mild infection, follow-up time point (3 vs 6 months), 
tacrolimus use, mycophenolate mofetil use, and ribavirin treatment were 
selected as independent variables. Severe vs mild infection was defined 
by the acute FEV1 loss during infection compared to the average of a pe-
riod of 4 months pre-infection (see section 2.2.). By considering this vari-
able in the model, a possible association of severe infection characterized 
by marked acute FEV1loss during infection with long-term FEV1 decline 
could be analyzed. The selection of variables was based on previously 
published risk factors, and a directed acyclic graph was constructed for 
assessment of potential confounding (Figure S1).12,31 First, the most ap-
propriate covariance structure was selected using restricted maximum 
likelihood and Akaike's information criterion. This was followed by vari-
able selection using backward elimination, and lastly the final model was 
analyzed with restricted maximum likelihood to provide proper estimates 
of the associations of the variables with FEV1 and their P-value. CLAD 
incidences were analyzed using multiple logistic regression with back-
ward selection using the same independent variables. Variables are re-
ported as unadjusted odds ratios (uORs) and adjusted odds ratios (aORs). 




From December 2008 until March 2018, 115 individual patients 
tested positive in 159 events for a respiratory PV/PMV infection 
(24 patients with two cases were included). Twenty cases were ex-
cluded from analysis due to infection within 6 months posttrans-
plant (n = 11), co-infected with invasive aspergillosis (n = 4), episode 
of acute rejection preceding infection (n = 4), or missing data (n = 1). 
Patient demographics and detected PV/PMV are shown in Table 1.
Most cases of PV/PMV infection occurred from December 
through March, with a lower incidence during the summer, when PIV 
was predominant (Figure 1). Initial infection was most often diag-
nosed in a nasopharyngeal swab sample (73%, mediancycle thresh-
old value (Ct-value) 25; interquartile range [IQR] 10.0), followed by 
nasal wash (14%, median Ct-value 23; IQR 7.3), throat swab (6%, 
median Ct-value 28; IQR 6.5), bronchoalveolar lavage (4% median 
Ct-value 23; IQR 5.8) and sputum samples (1%, median Ct-value 
24.5). The FilmArray panel was used in 22 nasopharyngeal swab 
samples, resulting in 16% of the total cases. Repeat viral testing 
after initial diagnosis was performed in 66 patients (48%) ranging 
from 7 to 30 days. Data on development of Ct-values in this time-
frame are shown in Figure S1. Symptoms, FEV1 loss at presentation 
and new radiologic abnormalities did not differ between the PV/
PMV (Table 2). Supplemental oxygen therapy was required in 17% 
of cases (PIV 28%, RSV 13%, hMPV 9%). Chest x-ray abnormali-
ties were mostly absent (72%) and nonspecific. Three patients died 
during follow-up (range 139-157 days postinfection), all unrelated to 
PV/PMV infection (1 renal failure/liver failure, 1 fasciitis necroticans, 
1 metastasized squamous cell carcinoma). Ribavirin was primarily 
taken orally, comprising 85% of all ribavirin-treated cases. Median 
duration of treatment was 10 (IQR 4) days and 9 (IQR 3) days for oral 
or aerosolized ribavirin, respectively.
3.2 | Lung function and CLAD
Median FEV1 at the different time points for the subgroups is illus-
trated in Figure 2. FEV1 dropped notably during infection, with a me-
dian acute loss compared to preinfection FEV1 of 14% (IQR 22), 15% 
(IQR 14), and 16% (IQR 20) for RSV, hMPV, and PIV, respectively. 
In total, 23 patients (17%) did not return to >90% of their preinfec-
tion FEV1 value at 6 months postinfection (7 RSV, 6 hMPV, 10 PIV). 
For the multivariate analysis of long-term FEV1 at 3 and 6 months 
postinfection, the variable selection approach identified ribavirin 
treatment (independent of time point), time since transplantation, 
their interaction, and severe infection as significant factors associ-
ated with long-term FEV1 (Table 3). The other independent variables 
did not reach statistical significance or improved model fit and were 
omitted during the backward selection process (Table S1).
In the final model there was an overall positive association of 
ribavirin treatment vs no ribavirin treatment on long-term FEV1 at 
3 and 6 months postinfection of (estimate [95% confidence interval 
CI] 13.23% [7.79; 18.67]) and a negative association for severe vs 
mild infection of (estimate [95% CI] −11.07 [−14.76; −7.37]) (Table 3). 
The interaction between time since transplantation and ribavirin 
treatment suggested a weaker positive association for ribavirin 
treatment when patients with longer period after transplantation.
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There was an overall high CLAD incidence with 26 of 127 patients 
(20%) having developed new or progressed CLAD at 6 months post-
infection (13 new CLAD, 13 progressed CLAD). CLAD incidence was 
higher in patients with a severe infection compared to mild infection 
(21/78 [27%] vs 5/49 [14%], P = .03). There were no patients who 
developed restrictive allograft syndrome (RAS, or rCLAD) during 
the follow-up period after infection. Univariate analysis showed a 
lower incidence of newly developed CLAD in patients treated with 
TA B L E  1   Patient demographics
All 
patients Severe infection Mild infection
Total No ribavirin Ribavirin P
No 
ribavirin Ribavirin P
Patients 139 33 55 35 16
Age at infection, y (IQR) 54.1 (20) 55.1 (13) 54.8 (13) .64 48.0 (23) 54.9 (24) .47
Gender, female (%) 72 (52) 19 (56) 26 (47) .39 19 8 (50) >.99
Time since transplantation, y (IQR) 3.9 (5) 4.1 (5) 3.9 (3) .41 3.1 (6) 4.0 (9) .97
Transplantation type: double, n (%) 111 (80) 29 (88) 40 (73) .12 28 (80) 14 (88) .70
Single, n (%) 26 (19) 4 (12) 1 3 (24) .27 7 (20) 2 (13) .70
Heart-lung, n (%) 2 (1) 0 (0) 2 (4) .53 0 (0) 0 (0) —
Underlying disease, n (%)
COPD 54 (39) 15 (45) 23 (42) .83 11 (31) 5 (31) >.99
Cystic fibrosis 32 (23) 5 (15) 11 (20) .78 11 (31) 5 (31) >.99
Pulmonary hypertension 11 (8) 3 (9) 3 (5) .67 5 (14) 0 (0) .17
Fibrosis 20 (14) 5 (15) 9 (16) >.99 3 (9) 3 (19) .36
Alpha-1a  10 (7) 2 (6) 5 (9) .71 2 (6) 1 (6) >.99
Otherb  12 (9) 3 (9) 4 (7) >.99 3 (9) 2 (13) .64
Virus, n (%)
RSV 40 (29) 9 (27) 15 (27) >.99 9 (26) 7 (44) .33
hMPV 46 (33) 12 (36) 18 (33) .82 11 (31) 5 (31) >.99
Parainfluenza 53 (38) 12 (36) 22 (40) .82 15 (43) 4 (25) .35
Parainfluenza type 1 14 (10) 5 (15) 3 (5) .25 5 (14) 1 (6) .65
Parainfluenza type 2 4 (3) 1 (3) 1 (2) >.99 2 (6) 0 (0) >.99
Parainfluenza type 3 26 (19) 6 (18) 13 (24) .60 5 (14) 2 (13) >.99
Parainfluenza type 4 9 (7) 0 (0) 5 (9) .15 3 (9) 1 (6) >.99
Co-infection, rhinovirus 5 (4) 0 (0) 3 (5) .29 1 (3) 1 (6) .53
Coronavirus 6 (4) 1 (3) 4 (7) .65 0 (0) 1 (6) .31
Bacterial 6 (4) 1 (3) 2 (4) >.99 2 (6) 1 (6) >.99
Immunosuppressive medication, n (%)
Cyclosporin 6 (4) 3 (9) 2 (4) .36 1 (3) 0 (0) >.99
Tacrolimus 124 (89) 26 (79) 52 (95) .04 32 (91) 14 (88) .64
Mycophenolic acid 109 (78) 26 (79) 44 (80) >.99 27 (77) 12 (75) >.99
Azathioprine 15 (11) 4 (12) 5 (9) .72 5 (14) 1 (6) .65
mTOR inhibitor 15 (11) 4 (12) 3 (5) .42 5 (14) 3 (19) .69
Pre-infection CLAD, n (%) 41 (29) 13 (39) 17 (31) .49 7 (20) 4 (25) .72
FEV1 at presentationc  (IQR) 84.7 (18) 81.0 (11) 78.0 (15) .15 96.8 (5) 94.7 (5) .32
Symptom onset to diagnosis, d 7 (5) 7 (9) 6 (3) .15 7 (5) 4 (10) .13
Note: Continuous data are displayed as medians with interquartile range (IQR).
Abbreviations: hMPV, human metapneumovirus; mTOR, mammalian target of rapamycin; RSV, respiratory syncytial virus.
aAlfa-1 antitrypsin deficiency. 
bOther underlying disease (histiocytosis, sarcoidosis, Stevens-Johnson syndrome, graft versus host disease, bronchiectasis). 
cDuring infection, as percentage of average FEV1 four months preinfection. 
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ribavirin for severe infection, whereas this difference was not signifi-
cant for progressed CLAD or patients with mild infection (Table 4). In 
case of severe infection PIV had the highest CLAD incidence with 10 
of 29 patients (34%), followed by RSV (5/20, 25%) and hMPV (6/29, 
21%); however, these differences were not statistically significant 
(P = .47). CLAD incidences per individual virus and treatment group 
are available in Table S5.
The multiple logistic regression analysis of new or progressed 
CLAD at 6 months yielded findings similar to the long-term FEV1 end 
point, with an association identified for severe infection and ribavirin 
treatment. There was a strong association between severe infection 
and development of new or progressed CLAD (uOR [95% CI] 2.89 
[1.14; 7.29]; aOR [95% CI] 4.63 [1.66; 12.88]), whereas ribavirin 
treatment was associated with a lower incidence (uOR [95% CI] 0.37 
[0.16; 0.85]; aOR [95% CI] 0.24 [0.10; 0.59]). In addition, the use of 
mycophenolate mofetil as part of standard immunosuppression was 
associated with a lower rate of new or progressed CLAD (uOR [95% 
CI] 0.46 [0.19; 1.12]; aOR [95% CI] 0.38 [0.14; 0.97]. We found no 
differences in outcome between the different ribavirin regimens in 
an exploratory analysis (Figure S3).
Hemoglobin levels during treatment were available in 64 patients 
treated with ribavirin (94%) and 28 patients in the non-ribavirin sub-
group (39%) and are reported in Table 5. Five patients treated with 
oral ribavirin developed de novo or progressive anemia during infec-
tion (9%), 2 of whom required blood transfusion and therapy cessation.
4  | DISCUSSION
This study showed that PV/PMV infection was associated with 
a high CLAD incidence for all studied viruses, and the severity of 
infection was associated with recovery of lung function with an 
increased likelihood of new or progressed CLAD in case of severe 
infection compared to mild infection. It is encouraging that ribavirin 
treatment showed a positive association with a reduced CLAD inci-
dence as well as FEV1 recovery.
F I G U R E  1   Seasonal distribution 
of PV/PMV infections. hMPV, human 
metapneumo virus; PIV, parainfluenza 
virus; RSV, respiratory syncytial virus
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The yearly incidence of PV/PMV infections in our study was 
approximately 5%, which is comparable with earlier studies.5,9 
Because patients in our center are only tested on clinical indication 
instead of routine screening, the real incidence may be higher es-
pecially for mild or asymptomatic PV/PMV infection.9,10,21 The im-
pact of these asymptomatic or mild infections is unclear, however, 
which is underscored by the outcome in our mild infection cohort. 
Outcome in these patients was better than in patients with a se-
vere infection, regardless of antiviral treatment. This is analogous 
to other reports of mild infection.13,16,32 Therefore, not diagnosing 
subclinical infections may not be significantly detrimental for the 
allograft function of patients and therefore warrant abstinence of 
antiviral treatment.
A recent large study by Allyn et al7 investigating viral respi-
ratory infections in LTR emphasized this nuance in severity of in-
fection by showing that viral pneumonia (indicated by chest x-ray 
infiltrate) increased the risk of allograft dysfunction or graft loss, 
while asymptomatic infection or symptomatic infection without 
radiographic infiltrates did not. Another recent study found that 
viral lower respiratory tract infection (defined based on lower 
tract symptoms or radiography) but not positivity for a virus in 
general, is a risk factor for CLAD development.16 This emphasizes 
the need to focus on severity of infection rather than sample pos-
itivity as the sole factor. Most of our patients had no radiographic 
abnormalities at presentation despite a pronounced acute FEV1 
loss. An acute FEV1 loss may be indicative of infection of the lower 
respiratory tract with activation of the immune response causing 
inflammation of the small airways yielding swelling and limiting 
airflow, thereby forming a risk factor for worse outcome.33-36 
Moreover, because PV/PMV infections often do not show radio-
graphic abnormalities, the amount of acute FEV1 loss may be a 
useful clinical marker for severe or mild infection and could guide 
treatment decisions.
The impact of PIV infections is described far less in LTR compared 
to hMPV and RSV. We found here that PV/PMV type was not a sig-
nificant factor in our multivariate models and that severe infections 
were equally often caused by RSV, hMPV, and PIV. Furthermore, PIV 
was not only the most commonly detected agent, but severe infec-
tion, supplemental oxygen requirement, and CLAD incidence were 
all highest in cases with PIV. As such, infection with PIV should not 
be underestimated and be regarded of at least similar severity as 
hMPV and RSV.
Although ribavirin treatment has been reported for all PV/PMV 
in LTRs, with most literature concerning RSV, current evidence is 
mostly limited to small studies and univariate analyses, thereby lim-
iting assessment of its efficacy.2,5,9,13,22,37 To our knowledge, a study 
by Fuehner et al is currently the only available prospective study 
comparing ribavirin vs no ribavirin in LTRs with a PV/PMV infection.5 
They compared LTRs who received oral ribavirin (n = 38) for RSV, 
hMPV, or PIV infection to those who did not due to contraindica-
tions (n = 29) and found a lower incidence of new CLAD at 6 months 
in the ribavirin group (5% vs 24%, P = .02, uOR [95% CI] 0.17 [0.03; 
0.88]). In contrast, high CLAD incidences up to 20% have also been 
described in LTRs who received systemic ribavirin for RSV or hMPV.4 
Furthermore, although successful treatment of hMPV and PIV has 
been described,5,6,21,24,38 no consensus exists whether to treat these 
infections with ribavirin.
Our study had several strengths to address these questions and 
assess the impact of PV/PMV infections and to make an estimation 
of associations of ribavirin treatment with outcome. The large sam-
ple size of the cohort and regularly scheduled follow-up at our center 
resulted in detailed clinical data that allowed a multivariate analysis, 
taking into account multiple infectious and non-infectious factors 
that could influence outcome, thereby minimizing confounding.7,12,31 
Using this strategy our study showed that ribavirin treatment, in-
dependent of the individual virus or other relevant factors, was as-
sociated with better long-term recovery of FEV1 postinfection and 
lower CLAD incidence. The interaction between ribavirin treatment 
and time since transplantation was likely attributable to ribavirin 
treated patients with an infection more recently after transplanta-
tion and may still have a slightly improving pulmonary function after 
transplantation.
Regarding the individual viruses, CLAD incidence was lower in 
case of ribavirin treated PIV whilst a trend was observed in case of 
ribavirin treated RSV or hMPV compared to no ribavirin. The high 








Severe infection 24 (60) 30 (65) 34 (64)
Hospitalized 15 (38) 17 (37) 24 (45)
Median FEV1 at 
presentationa  (IQR)
85.6 (22) 85.0 (14) 84.0 (20)
Respiratory symptoms 40 (100) 46 (100) 53 (100)
Cough 33 (83) 38 (83) 48 (91)
Sputum 19 (48) 28 (61) 34 (64)
Coryza 19 (48) 19 (41) 19 (36)
Fever 4 (10) 12 (26) 7 (13)
Dyspnea 17 (43) 12 (26) 28 (53)
Sore throat 7 (18) 2 (4) 3 (6)
Additional oxygen 
requirement
5 (13) 4 (9) 15 (28)
Chest X-ray 
abnormalities
10/36 (28) 11/43 (26) 13/50 (26)
Infiltrate 3 (8) 1 (2) 3 (6)
Pleural effusion 3 (8) 4 (9) 2 (4)
Consolidation 2 (6) 3 (7) 4 (8)
Bronchial cuffing 0 (0) 1 (2) 2 (4)
Increased interstitial 
markings
2 (6) 3 (7) 2 (4)
Increased pulmonary 
vasculature
1 (3) 2 (5) 0 (0)
Abbreviations: hMPV, human metapneumo virus; PIV, parainfluenza 
virus; RSV, respiratory syncytial virus.
aAs percentage of preinfection FEV1. 
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F I G U R E  2   FEV1 development over 
time per subgroup. FEV1 presented as 
percentage of pre-infection FEV1 for: 
(A) mild vs severe infection, (B) severe 
infection: ribavirin vs no ribavirin, (C) 
mild infection: ribavirin vs no ribavirin, 
(D) PV/PMV type. Data presented as 
medians + interquartile range. Asterisks 
indicate statistically significant differences 





Period (6 mo vs 3 mo) 0.480 [−1.701; 0.741] .440
Severe infection (vs mild infection) −11.07 [−14.76; −7.37] <.001
Ribavirin treatment (vs no ribavirin) 13.23 [7.79; 18.67] <.001
Time after transplantation
No ribavirin 0.427 [−0.117; 0.970] .130
Ribavirin −0.709 [−1.322; −0.096] .024
Note: Estimates are expressed as postinfection FEV1 as percentage of preinfection FEV1. Results 
of final hierarchical linear mixed model shown, full model available in Supplementary Material.
Abbreviation: CI, confidence interval.
TA B L E  3   Associations of variables on 
FEV1 at 3 and 6 months postinfection
n, (%)





New CLAD 7/19 (35) 3/37 (8) .01 2/28 (7) 1/12 (8) >.99
Progressed CLAD 7/10 (70) 4/12 (33) .20 2/5 (40) 0/4 (0) .44
Total CLAD 14/29 (48) 7/49 (14) <.01 4/33 (12) 1/16 (6) .66
Note: P value from Fishers exact test.
Abbreviation: CLAD, chronic lung allograft dysfunction.
TA B L E  4   Univariate analysis of CLAD 
incidences
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CLAD incidence of untreated severe PIV infection in our study of 
66% is comparable with two small studies reporting incidences of 
57% and 66% of untreated PIV cases.8,9
Given the possible detrimental effects of PV/PMV infection in 
LTR, and the in vitro susceptibility to ribavirin of PV/PMV, we be-
lieve ribavirin treatment for RSV, hMPV, and PIV may be considered 
an option until evidence from randomized controlled trials about its 
effectiveness or other treatment options are available.
Interestingly, we found a protective effect of mycophenolate 
mofetil as standard immunosuppression for the CLAD end point, but 
not for the FEV1 end point. Mycophenolate mofetil is the prodrug 
for mycophenolic acid, which has shown intrinsic antiviral poten-
tial against, amongst others, hepatitis C and E viruses, and PIV-3, 
through a similar antiviral mechanism as ribavirin.39-41
Having ambiguous results for the two different end points and 
a broad confidence interval, we cannot be certain there was a true 
influence of mycophenolate mofetil on graft function. However, this 
finding certainly warrants further investigation into the antiviral 
properties of mycophenolic acid, its interplay with ribavirin and the 
balance with immunosuppression.
We do note certain limitations exist inherent to the study design 
such as a selection bias for patients who were more critically ill and 
the lack of randomization, thereby limiting causal inference. In ad-
dition, different ribavirin treatment regimens have been used in our 
study; however, several studies showed comparable results using 
different treatment regimens for RSV.22,23,37,42,43 Finally, although 
we considered alternative factors explaining the outcomes in the 
ribavirin group, we did not identify associations for these factors. 
Nevertheless, we cannot exclude some degree of residual confound-
ing even with careful covariate selection based on previous literature 
and use of multivariate techniques. It is unlikely, however, that this will 
be of such magnitude that it would invalidate the main associations.
Considering the increased recognition of the importance of these 
non-influenza viral infections and the current state of evidence, a 
multicenter randomized controlled trial would be the next step to 
evaluate the true value of ribavirin for PV/PMV infections in LTRs. 
This is also important in light of upcoming new therapeutic options 
which should be compared to currently available options.
In conclusion, our data provide valuable information about the 
outcomes of LTRs with PV/PMV infections and suggests possible 
associations for ribavirin use and infection severity with long-term 
outcomes. However, well-designed prospective trials are needed to 
confirm these findings.
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